BR9915460A - Método de tratamento de febre hemorrágica virótica - Google Patents

Método de tratamento de febre hemorrágica virótica

Info

Publication number
BR9915460A
BR9915460A BR9915460-9A BR9915460A BR9915460A BR 9915460 A BR9915460 A BR 9915460A BR 9915460 A BR9915460 A BR 9915460A BR 9915460 A BR9915460 A BR 9915460A
Authority
BR
Brazil
Prior art keywords
treatment
hemorrhagic fever
viral hemorrhagic
provides
toxicity
Prior art date
Application number
BR9915460-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Charles Jack Fisher
Sau-Chi Betty Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9915460A publication Critical patent/BR9915460A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4866Protein C (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR9915460-9A 1998-11-20 1999-11-15 Método de tratamento de febre hemorrágica virótica BR9915460A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10915398P 1998-11-20 1998-11-20
PCT/US1999/027074 WO2000030677A1 (en) 1998-11-20 1999-11-15 Method of treating viral hemorrhagic fever

Publications (1)

Publication Number Publication Date
BR9915460A true BR9915460A (pt) 2001-07-17

Family

ID=22326085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915460-9A BR9915460A (pt) 1998-11-20 1999-11-15 Método de tratamento de febre hemorrágica virótica

Country Status (12)

Country Link
US (2) US6270764B1 (enExample)
EP (1) EP1131091B1 (enExample)
JP (1) JP2002530353A (enExample)
CN (1) CN1326356A (enExample)
AT (1) ATE235915T1 (enExample)
AU (1) AU2149800A (enExample)
BR (1) BR9915460A (enExample)
CA (1) CA2351470A1 (enExample)
DE (1) DE69906568T2 (enExample)
ES (1) ES2195655T3 (enExample)
IL (1) IL142220A0 (enExample)
WO (1) WO2000030677A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131091B1 (en) * 1998-11-20 2003-04-02 Eli Lilly And Company Treatment of viral hemorrhagic fever with protein c
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
HUP0500472A2 (hu) 2001-10-15 2005-08-29 Chiron Corporation Szepszis kezelése kis dózisú szöveti faktor bioszintézis inhibitor (TFPI) beadásával
US7132398B2 (en) 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
CA2560103A1 (en) * 2004-03-17 2005-11-24 Chiron Corporation Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
WO2007092607A2 (en) * 2006-02-09 2007-08-16 Genetech, Inc. Treatment of hemorrhagic viral infections using a tissue factor inhibitor
RU2379034C1 (ru) * 2008-11-17 2010-01-20 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Способ лечения геморрагической лихорадки с почечным синдромом
AU2016431615A1 (en) * 2016-12-08 2019-06-20 Cellphire, Inc. Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
WO2020112963A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
EP3887402A4 (en) 2018-11-30 2022-10-26 Cellphire, Inc. PLATELETS AS RELEASING AGENT
BR112021021984A2 (pt) 2019-05-03 2022-03-03 Cellphire Inc Materiais e métodos para produzir produtos de sangue
CN114450066A (zh) 2019-08-16 2022-05-06 塞尔菲乐有限公司 作为抗血小板剂逆转剂的血栓小体
CA3170201A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Methods of treating congenital hemophilia with anti-fibrinolytic loaded platelets
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
PE86299A1 (es) * 1997-04-28 1999-09-17 Lilly Co Eli Formulaciones de proteina c activada
EP1131091B1 (en) * 1998-11-20 2003-04-02 Eli Lilly And Company Treatment of viral hemorrhagic fever with protein c
IL140326A0 (en) * 1999-04-30 2002-02-10 Lilly Co Eli Protein c derivatives

Also Published As

Publication number Publication date
US6270764B1 (en) 2001-08-07
WO2000030677A1 (en) 2000-06-02
EP1131091B1 (en) 2003-04-02
IL142220A0 (en) 2002-03-10
DE69906568T2 (de) 2004-02-12
US6767539B2 (en) 2004-07-27
CA2351470A1 (en) 2000-06-02
US20010028880A1 (en) 2001-10-11
ES2195655T3 (es) 2003-12-01
AU2149800A (en) 2000-06-13
ATE235915T1 (de) 2003-04-15
EP1131091A1 (en) 2001-09-12
JP2002530353A (ja) 2002-09-17
DE69906568D1 (de) 2003-05-08
CN1326356A (zh) 2001-12-12

Similar Documents

Publication Publication Date Title
ATE234092T1 (de) 2-alkylpyrrolidine
BR9915460A (pt) Método de tratamento de febre hemorrágica virótica
TR200000782T2 (tr) Resorsinol türevleri.
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
TR199900083T2 (xx) Klaritromisinin kristal bi�imi I.
ATE253063T1 (de) 5-ht1f-agonisten
ATE210988T1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
DK0825857T3 (da) Anvendelse af gabapentin og derivater deraf til behandling af mani og bipolær lidelse
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
EP0318233A3 (en) Improvements in or relating to serotonin and norepinephrine uptake inhibitors
NO990849L (no) Substituerte 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyklohepta (b) benzofuraner
ID25478A (id) Agonis 5-ht1f
BR9915317A (pt) Método de tratar trombocitopenia induzida por heparina
DK1133314T3 (da) Protein C til behandling af seglcellesygdom og thalassæmi
EP0116628A4 (en) 1-ACYL-3-PYRIDYLMETHYLGUANIDINE AND THEIR USE AS AN ANI-HYPERTENSIVE.
BR9915984A (pt) Método de tratar púrpura trombocitopênica e sìndrome urêmica hemolìtica
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
ATE227997T1 (de) Pharmazeutische zusammensetzung zur nasalen verabreichung von thiocolchicosid
PT908107E (pt) Composicoes adocantes contendo neohesperidina-dihidrocalcona e pelo menos um outro adocante de elevada intensidade
IT1271685B (it) Impiego dei polidesossiribonucleotidi nelle neuropati diabetiche
PT1001789E (pt) Produto compreendendo pelo menos um arn de dupla helice em associacao com pelo menos um derivado do 6-benziluracilo para uma utilizacao terapeutica simultanea separada ou prolongada no tempo
FI954110A7 (fi) Menetelmä (1R,2R)-N-metyyli-2-(3-pyridyyli)-2-tetrahydrotiopyrankarbot iamodi-1-oksidin valmistamiseksi
ECSP003404A (es) Solucion acuosa estable de em 12 y procedimiento de preparacion de dicha solucion

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]